rs121913521
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Moderate
The NM_000222.3(KIT):c.1679T>A(p.Val560Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V560E) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000222.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
KIT | NM_000222.3 | c.1679T>A | p.Val560Asp | missense_variant | 11/21 | ENST00000288135.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
KIT | ENST00000288135.6 | c.1679T>A | p.Val560Asp | missense_variant | 11/21 | 1 | NM_000222.3 | P4 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Gastrointestinal stromal tumor Pathogenic:1Other:1
-, no assertion criteria provided | research | National Institute of Cancer Research, National Health Research Institutes | - | the literature - |
Likely pathogenic, no assertion criteria provided | literature only | Database of Curated Mutations (DoCM) | May 13, 2016 | - - |
Melanoma Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | Database of Curated Mutations (DoCM) | Jul 14, 2015 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 23, 2024 | The p.V560D variant (also known as c.1679T>A), located in coding exon 11 of the KIT gene, results from a T to A substitution at nucleotide position 1679. The valine at codon 560 is replaced by aspartic acid, an amino acid with highly dissimilar properties. This variant has been observed in at least one individual with a personal and/or family history that is consistent with KIT-related gastrointestinal stromal tumor syndrome (Ambry internal data). Protein functional studies have shown this amino acid to be critical (Ma Y et al. J Biol Chem, 1999 May;274:13399-402). This variant has been identified as a common somatic alteration in gastrointestinal stromal tumors (Taniguchi M et al. Cancer Res, 1999 Sep;59:4297-300; Tarn C et al. Clin Cancer Res, 2005 May;11:3668-77; Gomes AL et al. Am J Clin Pathol, 2007 Jan;127:89-96; Steigen SE et al. APMIS, 2007 Apr;115:289-98; Tokunaga M et al. Intern Med, 2018 Jun;57:1719-1723). Close match alterations (p.V560del, p.V560G) have been observed as germline variants that segregate with disease in patients with gastrointestinal stromal tumors (Kang DY et al. Am J Surg Pathol, 2007 Feb;31:224-32; Bamba S et al. Intern Med, 2015 Apr;54:759-64). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at